Redefining HER2 in Breast Cancer: Insights on HER2-Low and Ultra-Low Treatment Advances

Watch as Dr. VK Gadi and Dr. Anne O’Dea address advances in treating HER2-expressing breast cancer, and dive deep into the latest thoughts around HER2 as a spectrum rather than a binary positive/negative diagnostic. Patients with HER2-low (1+ or 2+ by immunohistochemistry but FISH-negative) and ultra-low levels were traditionally HER2-negative. However, the DESTINY-Breast04 and DESTINY-Breast06 trials showed that T-DXd (trastuzumab deruxtecan) can improve progression-free and overall survival in HER2-low or ultra-low expression patients compared to chemotherapy.

Watch their this portion of their discussion below to learn more about how moving from a binary HER2-positive/negative to a nuanced knowledge of HER2 expression is changing treatment options.